Table 3.
Current treatment and ocular data regarding scleritis grading and number of relapses in our cohort of patients.
| Patient | Ongoing treatment and dosage | Indication | Treatment duration (months) | Scleritis grading before therapy RE |
Scleritis grading at last follow-up RE |
Scleritis grading before therapy LE |
Scleritis grading at last follow-up LE |
No. of relapses 12 months preceding therapy | No. of relapses after 12 months of therapy | No. of relapses at last follow-up | cDMARDs | GCs§ | AE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RTX∗ | Scleritis | 7 | 2 | 0 | 0 | 0 | 3 | NC | 0 | MFA | 10 | — |
| 2 | RTX 2 gr | Scleritis | 1 | — | — | 4 | 0 | 3 | NC | 0 | — | — | # |
| 3 | RTX∗ | Scleritis | 15 | — | — | 4 | 0 | 3 | 0 | — | LFN | 5 | — |
| 4 | RTX 2 gr/6 months | Scleritis | 12 | 3 | 4 | — | — | 3 | — | — | — | — | — |
| 5 | RTX 2 gr/6 months | Systemic | 30 | 2 | 0 | — | — | 1 | 0 | — | AZA | — | — |
| 6 | TCZ 162 mg/week | Scleritis | 3 | 0 | 0 | 2 | 0 | 3 | NC | 0 | — | — | — |
| 7 | TCZ 162 mg/week | Scleritis | 28 | 2 | 0 | — | — | 4 | 1 | — | — | 5 | — |
| 8 | ANA 100 mg/day | Scleritis | 1 | 4 | 3 | — | — | 3 | NC | 0 | — | 2.5 | — |
| 9 | ANA 100 mg/day | Scleritis | 3 | 4 | 0 | 0 | 0 | 3 | NC | 0 | MTX | 12.5 | — |
| 10 | ANA 100 mg/day | Scleritis | 44 | — | — | 1 | 0 | 1 | 0 | — | — | — | — |
| 11 | ABA 125 mg/week | Systemic | 24 | 4 | 4 | 3 | 3 | 4 | 3 | — | — | — | — |
| 12 | ABA 125 mg/week | Systemic | 56 | — | — | 1 | 0 | 1 | 0 | — | MTX | — | — |
| 13 | ABA 125 mg/week | Systemic | 15 | — | — | 2 | 0 | 1 | 0 | — | MTX | — | — |
| 14 | TFC 5 mg twice daily | Systemic | 6 | 0 | 0 | 2 | 0 | 1 | NC | — | — | 5 | — |
ABA: abatacept; ANA: anakinra; AE: adverse event; AZA: azathioprine; cDMARDs: conventional disease-modifying antirheumatic drugs; GCs: glucocorticoids; LE: left eye; LFN: leflunomide; MFA: mycophenolic acid; MTX: methotrexate; No.: number; NC: not calculable; RE: right eye; RTX: rituximab; TCZ: tocilizumab; TFC: tofacitinib. ∗2 loading dose infusions of 1000 mg separated by 2 weeks and 500 mg every 6 months thereafter. #Pneumonia and septic shock. §Daily intake of glucocorticoids (prednisone or equivalent expressed in mg).